Ref. 65-2023 Postdoctoral Fellow

The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Fellow”

Reference: Ref. 65-2023

Application deadline: 30/11/2023

Number of vacancies: 1

The Vall d´Hebron Institute of Oncology´s (VHIO) Upper Gastrointestinal Cancer Translational Research Group headed by Dr. Teresa Macarulla MD PhD is recruiting a postdoctoral fellow.
Group description:
The Upper Gastrointestinal (GI) Cancer Translational Research Group at the prestigious Vall d’Hebron Institute of Oncology (VHIO) is a dynamic and innovative team of clinical and translational researchers. Our group is dedicated to advancing pancreaticobiliary cancer research from bench to bedside, focusing on three key areas.

First and foremost, we are dedicated to unraveling prognostic and predictive factors related to targeted and immune therapies. We are interested in identifying potential biomarkers based on transcriptional, epigenetic, and metabolic features. Our goal is to unearth biomarkers that can effectively forecast patient responses to these treatments, thus enabling us to offer personalized therapeutic options that enhance overall patient outcomes. Additionally, we are actively engaged in creating patient-derived models that hold significant relevance for preclinical investigations. These models serve as invaluable tools for advancing our understanding of upper GI cancers and evaluating potential treatment strategies. Furthermore, we are committed to conducting rigorous preclinical and clinical assessments of novel therapeutic approaches. Our particular emphasis lies in developing molecular therapies designed to target the aberrant signaling pathways associated with pancreatic and bile duct cancers. In this regard, our group has made pioneering contributions, leading early-phase clinical trials and spearheading translational studies to fortify anti-cancer strategies for upper GI malignancies.

Here are several examples of our work:

Elife 12, doi:10.7554/eLife.83951 (2023).
Clin Cancer Res 29, 432-445, (2023).
Clin Cancer Res 28, 1662-1671, (2022).
Eur J Cancer 171, 232-241, (2022).
Eur J Cancer 175, 299-310, (2022).
J Clin Oncol 40, 3929-3939, (2022).
JAMA Oncol 7, 1669-1677, (2021).
Lancet Gastroenterol Hepatol 6, 803-815, (2021).
J Clin Oncol 39, 1108-1118, (2021).
Nat Med 26, 878-885, (2020).
Nat Genet 52, 655-661, (2020).
Lancet Oncol 21, 796-807, (2020).
Nat Cell Biol 21, 824-834, (2019).
J Clin Oncol 37, 230-238, (2019).
N Engl J Med 381, 317-327, (2019).
Cell Stem Cell 23, 727-741 e729, (2018).

Job description:

We seek an enthusiastic postdoctoral fellow willing to participate in our translational project supported by the European Transcan-3 program. This project is at the interface of clinical and preclinical studies. The fellow will have the opportunity to work with many high-throughput techniques to study transcriptional, epigenetic, and metabolic dysregulations found in GI cancer patients (e.g., RNA-seq, ChIP-seq, ATAC-seq, MeDIP-seq, metabolomics) as well as the use of patient-derived preclinical models to perform drug screens ex vivo and in vivo. Moreover, we encourage the fellow to acquire bioinformatics competence for genome-wide data analysis. The fellow will work within an international consortium of groups from Spain, Germany, and Israel.


• This offer is open to candidates of any nationality.
• Candidates must have obtained a PhD (biomedical-related areas) or MD.
• Candidates who expect to be awarded a PhD or MD degree by December 2023 are eligible to apply.
• Candidates must have an excellent academic record and be the principal author of at least one peer-reviewed publication.
• Candidates must have a high working knowledge of English.
• To be successful in this application, the candidate will be a very organized, motivated, team-oriented individual.

Working Conditions:

• Salary will be negotiated according to the institutional guidelines.
• Start date: December 1st 2023

Candidates must submit a curriculum vitae, a cover letter, and contact information of at least two references to the preclinical and translational team leader Dr. Tian Tian MD PhD via email to:, including the reference “2023 Upper GI Postdoctoral Fellow Application” in the subject line of your email. The selection committee will review applications immediately; short-listed candidates will be scheduled for online or on-site interviews.

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO’s translation toward precision oncology:

Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.